Volume 15, Number 3—March 2009
Dispatch
Evaluation of Commercially Available Anti–Dengue Virus Immunoglobulin M Tests
Elizabeth A. Hunsperger, Sutee Yoksan, Philippe Buchy, Vinh Chau Nguyen, Shamala D. Sekaran, Delia A. Enria, Jose L. Pelegrino, Susana Vázquez, Harvey Artsob, Michael Drebot, Duane J. Gubler, Scott B. Halstead, María G. Guzmán, Harold S. Margolis, Carl-Michael Nathanson, Nidia R. Rizzo Lic, Kovi E. Bessoff, Srisakul Kliks, and Rosanna W. Peeling
Table 1
Panels used for evaluation of 350 serum samples from patients with positive and negative results for IgM to DENV*
| Evaluation panel | No. samples |
|---|---|
| DENV IgM positive | |
| From primary infections | 27 |
| From secondary infections | 154 |
| Total positive |
181† |
| DENV IgM negative | |
| DENV positive/DENV IgM negative | 19 |
| DENV IgG positive |
7 |
| Related flavivirus IgM positive | |
| West Nile virus positive | 25 |
| Yellow fever virus positive |
4 |
| Related flavivirus IgG positive | |
| West Nile virus positive | 1 |
| Yellow fever virus positive | 10 |
| St. Louis encephalitis virus positive | 2 |
| Japanese encephalitis virus positive |
10 |
| Febrile illness | |
| Lyme disease IgG positive | 9 |
| Malaria | 31 |
| New World hantavirus IgM positive |
7 |
| Systemic conditions | |
| Rheumatoid factor | 6 |
| Systemic lupus erythematosus |
2 |
| Healthy persons‡ | |
| Negative |
36 |
| Total negative | 169 |
*DENV, dengue virus; Ig, immunoglobulin.
†No. serum samples identified as serotype specific: 26 DENV-1, 19 DENV-2, 13 DENV-3, and 7 DENV-4. Serotype was not identified for 116 samples.
‡From areas where dengue is not endemic.
